Radar Telegram alerts Open Radar

Biocad eliminated the pain.

תרגם לעברית

Икона Фармы · · Source

Biocad eliminated the pain.

Biocad has registered a new form of the biological drug Delibera (adlimumab): the concentration has been doubled - 40 mg is now in 0.4 ml instead of 0.8 ml, citrate has been removed from the composition, which reduces the pain of injection. Bioequivalence was confirmed in study BCD-057-5 in 443 healthy volunteers.

"Innovation" in this case is removing something that caused pain from the syringe and calling it a breakthrough in drug development. In fact, it is a cosmetic improvement of the old adlimumab under a new round of patent protection and marketing "now it doesn't hurt at all to inject". Domestic import substitution at its best: bioequivalence in healthy volunteers, not clinical results in real patients.

Of course, for long-term IBD/rheumatology patients, the injection volume is smaller and the absence of citrate actually reduces discomfort - a small thing, but with daily/weekly treatment for years it has cumulative importance.

More on Radar

Want to see every report in real time?

Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.

Sign up free
Share on WhatsApp Get alerts on Telegram